Cyclo Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Cyclo Therapeutics with a Buy rating and $3 price target. Cyclo is a clinical stage biotechnology company focused on developing a cyclodextrin-based therapies to treat neurological disorders, the analyst tells investors in a research note. The firm currently projects the company to generate revenues of $412M in 2031 and believes Cyclo at current valuation levels is an attractive opportunity for a long-term investor.